腺泡状软组织肉瘤的诊断、预后与治疗综述
本文综述1952年至2018年3月发表的文献,聚焦腺泡状软组织肉瘤(ASPS)的分子诊断与治疗进展。ASPS由t(X;17)(p11;q25)易位驱动,对多柔比星化疗耐药但转移后生存期长;舒尼替尼、西地尼布和帕唑帕尼等酪氨酸激酶抑制剂在超过50%的病例中实现肿瘤缓解或疾病稳定,免疫检查点抑制剂亦提供新策略。
要点
- ASPS为t(X;17)(p11;q25)易位驱动的罕见软组织肉瘤,常累及年轻成人。
- 酪氨酸激酶抑制剂在超过50%病例中实现肿瘤缓解或疾病稳定。
- 免疫检查点抑制剂及靶向TFE3相关免疫微环境为新兴治疗方向。
核心结论
- ASPS特征性基因组事件的生物学结局仍在研究中,对肿瘤微环境和多条激活通路的深入理解应促成更合理的治疗。
- 鉴于新药与患者结局的关联,目前断言所有转移性ASPS均不可治愈为时过早。
研究设计与样本
- 本综述纳入1952年至2018年3月1日之间发表的文章。
主要发现
- ASPS常影响年轻成人,表现为惰性行为但早期即有转移播散证据。
- 自1952年ASPS被确认为独立实体后,回顾性数据显示转移患者生存期延长,尽管对多柔比星为基础的常规化疗存在内在耐药。
- 识别t(X;17)(p11;q25)易位及其对应的ASPSCR1-TFE3融合蛋白所激活的分子通路,为药物开发开辟新路径。
- TFE3与免疫抑制微环境的关联为探索影响T效应细胞与T调节细胞平衡的治疗提供依据。
- 舒尼替尼、西地尼布和帕唑帕尼等酪氨酸激酶抑制剂在超过50%的病例中显示肿瘤缓解或疾病稳定的活性。
临床怎么用
- 酪氨酸激酶抑制剂(如舒尼替尼、西地尼布、帕唑帕尼)可用于ASPS治疗,在超过50%病例中实现肿瘤缓解或疾病稳定。
- 针对TFE3相关免疫微环境的免疫检查点抑制剂策略值得探索。
- 篮子试验及聚焦特定信号通路与独特基因组特征疾病交叉的前瞻性研究将提供新的治疗选择。
局限性
- 本综述纳入文献截至2018年3月1日,后续新证据未涵盖。
- ASPS特征性基因组事件的生物学结局仍在研究中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alveolar soft-part sarcoma (ASPS) is a rare, translocation-driven sarcoma of the soft tissues. Alveolar soft-part sarcoma often affects young adults and is characterized by indolent behavior but early evidence of metastatic spread. After recognition of ASPS as a specific entity in 1952, retrospective data indicated prolonged survival in patients with metastases, despite inherent resistance to conventional doxorubicin-based chemotherapy. Tyrosine kinase inhibitors and immune checkpoint inhibitors have provided unexpected new treatment strategies for ASPS. OBSERVATIONS: This review includes articles published between 1952 and March 1, 2018. With the introduction of new molecular diagnostic tools and therapies, the distinctive features of ASPS have become more evident. The identification and better understanding of molecular pathways activated by the characteristic t(X;17)(p11;q25) translocation and its correspondent chimeric ASPSCR1-transcription factor E3 (TFE3) fusion protein open new paths to drug development. The associations of TFE3 and facilitation of an immunosuppressive microenvironment provide a rationale for exploring treatments that affect the balance between T-effector cells and T-regulatory cells. Tyrosine kinase inhibitors, such as sunitinib, cediranib, and pazopanib, show activity with either tumor responses or disease stabilization in more than 50% of the cases. Given the association of new agents with patient outcomes, it is too early to say whether metastatic ASPS should still be considered incurable in all patients. CONCLUSIONS AND RELEVANCE: The biologic outcomes of the canonical genomic event in ASPS remain under investigation; a better understanding of the tumor microenvironment and the multiple pathways activated in this sarcoma, including unusual bioenergetics, MET signaling, and angiogenesis, should lead to more rational therapy. Basket trials and related prospective studies focusing on the intersection of specific signaling pathways and diseases with unique genomic features, such as ASPS, will provide an understanding of new options for care.
引用
- Paoluzzi L, Maki RG. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review. JAMA Oncol. 2019. PMID: 30347044. doi:10.1001/jamaoncol.2018.4490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。